Imatinib in active diffuse cutaneous systemic sclerosis: Results of a six-month, randomized, double-blind, placebo-controlled, proof-of-concept pilot study at a single center-Reference-Cited by-同舟云学术

Imatinib in active diffuse cutaneous systemic sclerosis: Results of a six-month, randomized, double-blind, placebo-controlled, proof-of-concept pilot study at a single center

Published:2011-10-28 Issue:11 Volume:63 Page:3547-3551
ISSN:0004-3591
Container-title:Arthritis & Rheumatism
language:en
Short-container-title:Arthritis & Rheumatism

Author:

Pope Janet,McBain Donna,Petrlich Lisa,Watson Sharon,Vanderhoek Louise,de Leon Faye,Seney Shannon,Summers Kelly

Publisher

Wiley

Subject

Pharmacology (medical),Immunology,Rheumatology,Immunology and Allergy

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/art.30549/fullpdf

Reference16 articles.

1. A proposal of criteria for the classification of systemic sclerosis;Nadashkevic;Med Sci Monit,2004

2. Scleroderma (systemic sclerosis): classification, subsets, and pathogenesis;LeRoy;J Rheumatol,1988

3. Tyrosine kinase inhibitors for the treatment of fibrotic diseases such as systemic sclerosis: towards molecular targeted therapies;Distler;Ann Rheum Dis,2010

4. Uncontrolled expression of vascular endothelial growth factor and its receptors leads to insufficient skin angiogenesis in patients with systemic sclerosis;Distler;Circ Res,2004

5. Transforming growth factor β as a therapeutic target in systemic sclerosis;Varga;Nat Rev Rheumatol,2009

Cited by 105 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Brentuximab vedotin for skin involvement in refractory diffuse cutaneous systemic sclerosis, an open-label trial;Rheumatology;2024-04-23

2. Systemic Sclerosis;Rook's Textbook of Dermatology;2024-03-19

3. Progressive Interstitial Lung Disease Non-Responsive to Immunosuppressive Therapy;Scleroderma;2024

4. Rapid Diffuse Skin Disease with Progressive Joint Contractures;Scleroderma;2024

5. The long-term course of the Health Assessment Questionnaire in patients with systemic sclerosis;Journal of Scleroderma and Related Disorders;2023-06-21